*Sponsored

Krypton Street Announces Its Next Potential Breakout Idea!

Here’s What We Can Tell You About GeoVax Labs, Inc. (Nasdaq: GOVX)—So Far:

Limited Float: GeoVax Labs, Inc. (Nasdaq: GOVX) Has Around 10M Shares Available, Meaning Even A Small Shift In Demand Could Create The Potential For Significant Swings.

Under The Radar: With A Market Cap Of Approximately $15M As Of 3/11/2025, GeoVax Labs, Inc. (Nasdaq: GOVX) Appears To Be Flying Under

Wall Street’s Radar—For Now.

Analyst Coverage: Analysts Highlight GeoVax Labs, Inc. (Nasdaq: GOVX), With One Target Suggesting A 1,039% Upside Potential.

Advancing Pipeline: GeoVax Labs, Inc. (Nasdaq: GOVX) Is Progressing With Gedeptin In Phase 2 Trials And GEO-CM04S1 In Active Development.

Potential For $37B+ Market Growth: With The Biodefense Sector Expected To Surpass $37.16B By 2034, GeoVax Labs, Inc. (Nasdaq: GOVX) Aligns With A Rapidly Growing Industry.

Keep reading to get up to speed on GeoVax Labs, Inc. (Nasdaq: GOVX) and see why it’s topping our watchlist for Wednesday morning.

March 12, 2025

Dear Reader,

Please tell me you are watching GeoVax Labs, Inc. (Nasdaq: GOVX) right now.

GeoVax Labs, Inc. (Nasdaq: GOVX) is making moves—both on the charts and in the headlines.

Around 9:06 AM EST this morning, GeoVax Labs, Inc. (Nasdaq: GOVX) triggered 10 Bullish Signals on TradingView’s technical analysis tool, including the Momentum Indicator on the 1-minute time frame.

At the same time, the company announced its expansion into Europe, establishing its initial footprint in the UK.

This expansion strengthens GeoVax Labs, Inc. (Nasdaq: GOVX)’s global presence, reinforcing collaborations with top scientists, academic institutions, and manufacturing partners across the region.

It’s also expected to support the advancement of Gedeptin, currently in clinical trials for head and neck cancers, while furthering development across its vaccine and immunotherapy pipeline.

With momentum building on multiple fronts, GeoVax Labs, Inc. (Nasdaq: GOVX) is turning heads at a pivotal moment.

If you missed my previous email, keep reading to get up to speed and see why were so excited to bring you GeoVax Labs, Inc. (Nasdaq: GOVX).

The biotech and pharma space moves fast—one breakthrough can take a little-known company from obscurity to the spotlight in no time.

We are now turning our attention to GeoVax Labs, Inc. (Nasdaq: GOVX)and have it at the top of our watchlist this morning. (3/12/2025)

With a mission to address critical health concerns, GeoVax Labs, Inc. (Nasdaq: GOVX) is developing solutions for some of the most pressing medical challenges through cutting-edge science and strategic vision.

Flying Under The Radar With an Approximate $15M Market Cap, Analyst’s Target Suggests 1,039% Upside Potential…

According to Benzinga, D. Boral Capital has assigned an $18 target to (GOVX), which suggests over 1,039% upside potential from today’s $1.58 range.

Additionally, Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets, maintains a Bullish rating with a $12 target, underscoring GeoVax Labs, Inc. (Nasdaq: GOVX)’s clinical momentum.

LeBoyer notes that Gedeptin’s progress into Phase 2 trials is in line with expectations and highlights CM-04S1 as aiming to provide enhanced protection compared to existing options, with key clinical data anticipated in the first half of 2025.

Noble Capital Markets bases its $12 target on projected fiscal year 2026 earnings per share (EPS) of $1.45, discounted at 30% annually to reflect risks associated with the industry and market.

The firm also assigns GeoVax Labs, Inc. (Nasdaq: GOVX) an ‘Above Average’ fundamental rating, pointing to the company’s experienced management team, robust corporate governance, and strong competitive positioning.

As of yesterday’s date, 3/11/2025, GeoVax Labs, Inc. (Nasdaq: GOVX) hasa market cap of approximately $15M and a public float below 10M shares.

Companies with such small market capitalization and limited float often have significant growth potential, particularly if attention begins to increase.

Continue reading to discover why GeoVax Labs, Inc. (Nasdaq: GOVX) will be at the top of our watchlist tomorrow morning.

GeoVax Labs, Inc. (Nasdaq: GOVX) Strengthens Its Clinical Pipeline With Key Developments…

Its leading clinical candidate, GEO-CM04S1, has demonstrated enhanced immune responses in individuals with specific health conditions, such as Chronic Lymphocytic Leukemia (CLL).

This advancement aims to provide stronger immunity where it is needed most.

Another notable project is GEO-MVA, designed to address multiple strains of a global health concern.

Given the increasing demand for innovative solutions in public health, this approach provides an avenue for broader protection.

GeoVax Labs, Inc. (Nasdaq: GOVX)’s  research in oncology is also progressing, with Gedeptin currently in Phase 2 clinical trials.

This therapy explores new methods of targeting cancer cells and improving patient outcomes.

GeoVax Labs, Inc. (Nasdaq: GOVX) has also announced that its Phase 2 trial for Gedeptin, its gene therapy for recurrent squamous cell carcinoma of the head and neck (SCCHN), is expected to begin in the first half of 2025.

This therapy employs Gene-Directed Enzyme Therapy (GDEPT) technology, which enhances the effectiveness of treatment while minimizing its impact on surrounding healthy cells.

The trial will explore Gedeptin’s use in combination with immune-based therapies, supporting a multi-faceted approach to treatment.

Beyond its clinical pipeline, GeoVax Labs, Inc. (Nasdaq: GOVX) is also working to address broader national and global health concerns.

With a focus on strengthening preparedness efforts, the company is advancing technologies that align with the increasing demand for biodefense solutions.

Biodefense Spending Is Expected to Exceed $37B—GeoVax Labs, Inc. (Nasdaq: GOVX) Eyes Role in Future Advancements

The U.S. alone is projected to account for approximately $10.87B of this market, driven by increasing awareness of biological threats and the need for stronger preventive measures.

In 2023, North America contributed over 41% of global biodefense revenue, and this share is expected to expand as governments continue investing in national security and public health infrastructure.

With well-established production facilities and strategic programs aimed at mitigating risks, the U.S. remains a key player in advancing technologies that enhance preparedness and response capabilities.

GeoVax Labs, Inc. (Nasdaq: GOVX) has underscored the role of its Modified Vac-cin-ia Ankara (MVA) platform in supporting these efforts and helping to bolster U.S. biodefense capabilities.

By aligning with key recommendations from the “Bolstering U.S. Biodefense” report, the company is working to address critical gaps in medical preparedness and contribute to the resilience of national health initiatives.

Several aspects of GeoVax Labs, Inc. (Nasdaq: GOVX)’s ongoing initiatives directly support these national security objectives:

• Enhancing Supply Chain Security: GeoVax is reducing reliance on foreign manufacturing by transitioning to a next-generation production platform designed to strengthen domestic capabilities.
• Improving Readiness for Emerging Health Concerns: The development of adaptable solutions ensures preparedness for evolving challenges and strengthens overall response frameworks.
• Supporting Public Health Infrastructure: GeoVax’s research and development efforts align with national and global health strategies aimed at expanding medical capabilities.
• Advancing Scalable Medical Solutions: By refining platforms that allow for rapid response and large-scale production, GeoVax is working to ensure greater accessibility and efficiency in health preparedness efforts.

Expanding Areas of Focus

The need for advanced medical solutions continues to grow, providing multiple areas where GeoVax’s work may be impactful:

• Immune-Compromised Populations: GEO-CM04S1 is being evaluated for its ability to strengthen immune responses in targeted groups.
• Public Health & Safety: As certain health concerns persist worldwide, GEO-MVA is positioned to play a role in broad-scale protection efforts.
• Oncology Research: With a growing focus on immune-based treatments, GeoVax’s work in this field has the potential to contribute to new advancements in cancer care.

Recent Developments and Strategic Initiatives

GeoVax has remained proactive in responding to critical health concerns and forming partnerships that support its research. Recent developments include:

• Global Health Preparedness: GeoVax has acknowledged ongoing public health challenges and remains focused on addressing them through its scientific advancements.
• Focus on MVA-Based Platforms: The company continues to refine its Modified Vac-cin-ia Ankara (MVA)-based research, aiming to enhance effectiveness across multiple applications.
• Monitoring Emerging Health Trends: With new concerns arising, GeoVax is staying ahead by ensuring its developments align with current and future needs.
• Commitment to Accessibility: GeoVax has emphasized its goal of making its advancements widely available, particularly in areas where access remains limited.
• Clinical Progress: The company has been making strides in its programs, with its CM-04S1 candidate selected for further evaluation in a BARDA-sponsored Phase 2b study set to commence in the second half of 2025.

7 Reasons We’re Keeping an Eye on GeoVax Labs, Inc. (Nasdaq: GOVX) Early This Morning…

1. Limited Float: GeoVax Labs, Inc. (Nasdaq: GOVX) has approximately 10M shares in the float, meaning even a slight shift in demand could create the potential for significant swings.

2. Under the Radar: With a market cap of around $15M as of 3/11/2025, GeoVax Labs, Inc. (Nasdaq: GOVX) appears to be flying under Wall Street’s radar—until now.

3. Analyst Coverage: Analysts clearly highlight GeoVax Labs, Inc. (Nasdaq: GOVX)’s potential. With one analyst’s target suggesting 1,039% upside potential from today’s range.

4. Advancing Pipeline: GeoVax Labs, Inc. (Nasdaq: GOVX) is pushing forward with Gedeptin in Phase 2 trials and GEO-CM04S1 in active development.

5. Potential For $37B+ Market Growth: With the biodefense sector projected to surpass $37.16B by 2034, GeoVax Labs, Inc. (Nasdaq: GOVX)aligns itself with a rapidly expanding space.

6. Government Initiatives: The Bolstering U.S. Biodefense Report emphasizes the need for enhanced medical readiness, aligning with GeoVax Labs, Inc. (Nasdaq: GOVX)’s ongoing efforts.

7. Supply Chain Security: GeoVax Labs, Inc. (Nasdaq: GOVX) aims to strengthen domestic capabilities and reduce reliance on foreign production.

Consider Adding GeoVax Labs, Inc. (Nasdaq: GOVX) To Your

Radar This Morning…

Let’s be honest—GeoVax Labs, Inc. (Nasdaq: GOVX) isn’t on everyone’s radar… yet.

But those who are paying attention might be ahead of the curve.

While most people chase what’s already made headlines, this one appears to be still flying under the radar——and if history is any guide, this is where some of the most interesting moves tend to start.

Here’s what stands out:

• A biopharma advancing next-generation treatments with a pipeline pushing into Phase 2.
• A sector projected to exceed $37B, backed by increasing government focus.
• A tiny market cap and float, which historically have led to the potential for significant swings if demand starts to shift.

And let’s not overlook the analysts—one has set an $18 target, another is at $12—both signaling what could be significant upside potential from here.

So what’s next?

We have all eyes on GeoVax Labs, Inc. (Nasdaq: GOVX) right now.

Consider taking a look at (GOVX) this morning while it’s still early— and remember to do your own research.

GeoVax Labs, Inc. (Nasdaq: GOVX) tops today’s watchlist—take a look while it’s still early.

Around 9:06 AM EST this morning, GeoVax Labs, Inc. (Nasdaq: GOVX) triggered 10 Bullish Signals on TradingView’s technical analysis tool, including the Momentum Indicator.

Also make sure you keep a look out for my next update—it could be on its way at any moment.

Alex Ramsay

Co-Founder / Managing Editor

Krypton Street Newsletter

KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.

The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media.

Please see important disclosure information here: kryptonstreet.com/disclaimer/

*Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 03/11/2025 and ending on 03/12/2025 to publicly disseminate information about (GOVX:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC, or their members own shares of (GOVX:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/govx/#details